title: Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma.
abstract: OBJECTIVE
  The optimal adjuvant therapy for stage I uterine sarcoma remains unresolved and may consist of radiotherapy (RT), chemotherapy, hormonal therapy or observation. We analyzed the impact of adjuvant pelvic RT on overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), pelvic control (PC) and patterns of failure.
  
  
  METHODS
  A retrospective analysis of 157 patients with International Federation of Gynecology and Obstetrics FIGO stage I uterine sarcoma was performed. RT was given postoperatively to a dose of 45-51 Gy in 28-30 fractions.
  
  
  RESULTS
  The 5-year OS, CSS, DFS and PC was 58%, 62%, 47% and 72%, respectively. Adjuvant RT significantly improved PC (85% for RT group vs. 64% for non-RT group; p=0.02) but did not impact OS, CSS or DFS.
  
  
  CONCLUSIONS
  The addition of adjuvant pelvic RT significantly improved PC for patients with stage I uterine sarcoma. As systemic therapies continue to improve, optimal locoregional control may result in improved patient outcomes.
authors.affiliation: University of Wisconsin Department of Radiation Oncology, Madison, WI, U.S.A. wmagnuson@uwhealth.org.
authors.forename: William J
authors.initials: WJ
authors.lastname: Magnuson
authors.affiliation: John T. Vucurevich Cancer Care Institute, Rapid City, SD, U.S.A.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Petereit
authors.affiliation: University of Wisconsin Department of Radiation Oncology, Madison, WI, U.S.A.
authors.forename: Bethany M
authors.initials: BM
authors.lastname: Anderson
authors.affiliation: University of Wisconsin Department of Radiation Oncology, Madison, WI, U.S.A.
authors.forename: Heather M
authors.initials: HM
authors.lastname: Geye
authors.affiliation: University of Wisconsin Department of Radiation Oncology, Madison, WI, U.S.A.
authors.forename: Kristin A
authors.initials: KA
authors.lastname: Bradley
mesh_terms: D000328:Adult; D000368:Aged; D002296:Carcinosarcoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*
keywords: Radiotherapy; sarcoma; uterine